340B PATIENTS Act of 2025
The 340B PATIENTS Act of 2025 would strengthen and clarify the 340B Drug Discount Program. It would explicitly require drug manufacturers to offer discounted pricing for 340B drugs purchased by covered entities (hospitals, clinics, and health centers) regardless of how or where the drugs are dispensed, and it would prohibit manufacturers from placing conditions on purchase or use of those drugs that could limit access, delivery, or acceptable dispensing practices. The bill also codifies contract pharmacies as an eligible dispensing channel under 340B, meaning the same pricing rules and protections apply when a covered entity contracts with outside pharmacies to dispense 340B drugs to its patients. In addition, the bill creates enforceable penalties for violations by manufacturers (including civil monetary penalties for certain violations) and provides a mechanism for covered entities to bring claims of violations. It directs the Secretary to issue implementing regulations within 180 days of enactment. Overall, the aim is to preserve access to 340B discounts across dispensing channels, ensure contract pharmacies operate under the same protections as direct dispensing, and strengthen oversight of manufacturer compliance.